A Prospective Cohort Study of IgG4RD in China
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01670695|
Recruitment Status : Recruiting
First Posted : August 22, 2012
Last Update Posted : April 11, 2017
|Condition or disease|
Immunoglobulin G4-related disease (IgG4-RD) is a recently defined emerging clinical entity characterized by tissue infiltration by IgG4-positive plasma cells, tissue fibrosclerosis and elevated serum IgG4 concentration.
In this study, patients with IgG4-RD will be investigated, including clinical presentation, laboratory findings and imaging study. All patients will be treated by standard care and follow-uped for at least 6 months.
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||Cohort Study of Patients With IgG4-Related Disease|
|Actual Study Start Date :||January 2012|
|Estimated Primary Completion Date :||January 2032|
|Estimated Study Completion Date :||January 2032|
Patients with IgG4-RD, including sclerosing pancreatitis, sclerosing cholangitis, inflammatory pseudotumors, retroperitoneal or mediastinal fibrosis, interstitial nephritis, hypophysitis, sclerosing dacryoadenitis, sialadenitis (Mikulicz disease and Küttner's tumor), inflammatory aortic aneurysm, lymphadenopathy, or other inflammatory conditions.
- Clinical Response [ Time Frame: 6 months ]Clinical Response is measured by IgG4-RD Responder Index, including organ/site score and serum IgG4 level.
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01670695
|Contact: Hua Chen, MDemail@example.com|
|Deptment of Rheumatology, Peking Union Medical College Hospital||Recruiting|
|Beijing, Beijing, China, 100032|
|Contact: Wen Zhang, MD 86-10-69158795 firstname.lastname@example.org|
|Contact: Hua Chen, MD 86-10-69158797 email@example.com|
|Principal Investigator:||Wen Zhang, MD||Deptment of Rheumatology, Peking Union Medical College Hospital|
|Study Chair:||Fengchun Zhang||Deptment of Rheumatology, Peking Union Medical College Hospital|